Jagsonpal Pharmaceuticals Ltd
NSE:JAGSNPHARM
Jagsonpal Pharmaceuticals Ltd
NSE:JAGSNPHARM
Price:
193.31
INR
-0.1%
Market Closed
Market Cap:
₹12.9B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Jagsonpal Pharmaceuticals Ltd
NSE:JAGSNPHARM
|
IN |
|
A
|
Azorim Investment Development and Construction Co Ltd
TASE:AZRM
|
IL |
|
H
|
Huaibei Mining Holdings Co Ltd
SSE:600985
|
CN |
|
United States Lime & Minerals Inc
NASDAQ:USLM
|
US |
|
N
|
Nakayo Inc
TSE:6715
|
JP |
|
V
|
Vinci SA
OTC:VCISF
|
FR |
|
N
|
Nueva Expresion Textil SA
MAD:NXT
|
ES |
|
Technical Communications Corp
OTC:TCCO
|
US |
|
L
|
Lundin Energy AB
XBER:LYV
|
SE |
Multiples-Based Value
The
Multiples-Based Value for
Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM)
under the Base Case is
hidden
INR.
Compared with the current market price of 193.31 INR, the stock appears
hidden
.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
JAGSNPHARM Multiples-Based Value
LOCKED
Multiples Across Competitors
JAGSNPHARM Competitors Multiples
Jagsonpal Pharmaceuticals Ltd Competitors
Jagsonpal Pharmaceuticals Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| IN |
|
Jagsonpal Pharmaceuticals Ltd
NSE:JAGSNPHARM
|
12.9B INR | 4.6 | 31.5 | 20.5 | 24.7 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
887.6B USD | 13.6 | 43 | 29 | 31 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
574.2B USD | 6.1 | 21.4 | 14.9 | 18.3 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
236.2B GBP | 5.3 | 30.6 | 16.9 | 23.8 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4.1 | 19.6 | 11.6 | 13 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
300.5B USD | 4.6 | 16.5 | 10.2 | 12.4 | |
| CH |
|
Novartis AG
SIX:NOVN
|
234.4B CHF | 5.2 | 21 | 13 | 16.7 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 105.4 | -83.6 | 386.8 | 970 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.5 | 10.5 | 7.8 | 9.1 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
153.1B USD | 2.4 | 19.7 | 7.6 | 10.1 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118B USD | 2.5 | 16.7 | 7.1 | 8.7 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
